Medicare expands coverage for Alzheimer's drugs including Leqembi.

Medicare will now cover a new class of Alzheimer's drugs that target amyloid plaque in the brain, following a lobbying campaign by patient advocates and drugmakers. The drugs have generated controversy over safety and effectiveness, but advocates say they are the first glimmer of hope in treating a disease that robs patients of their memories and identities. Medicare's new policy expands the number of patients eligible to receive the drugs after they get FDA approval while allowing the agency to collect critical information on how the medications affect patients.